Search / Trial NCT06232772

Research on Novel Biomarkers for Early Diagnosis of Parkinson's Disease

Launched by YOUSHENG XIAO · Jan 22, 2024

Trial Information

Current as of October 07, 2024

Not yet recruiting

Keywords

Description

Social benefits: This technology has minimal harm (skin sampling diameter of 1mm), rather than surgical traumatic brain biopsy, which meets the minimum harm and maximum benefit; 1) Clear clinical diagnosis and differential diagnosis of diseases at once, avoiding repetitive examinations, effectively saving medical expenses and medical insurance funds; 2) Beneficial for early diagnosis and intervention, reducing social and economic burden; 3) Enhance the disease diagnosis and treatment capabilities of the region, enhance basic medical research, and enhance the medical level of the region. Cli...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • * Patients with clinically defined or probable PD:According to the 2015 MDS diagnostic criteria, patients diagnosed with "clinically confirmed PD" regardless of age, gender, and meeting Hoehn\&Yahr staging ≤ 2.5 were included as case group one, which met \[Parkinson's syndrome+at least two supportive criteria+no absolute exclusion criteria\]
  • * Patients with clinically probable PD:According to the 2015 MDS diagnostic criteria, patients diagnosed with "clinically probable PD", regardless of age or gender, and meeting Hoehn\&Yahr staging ≤ 2.5 were included as case group two, i.e. patients who met \[Parkinson's syndrome+no absolute exclusion criteria+1/2 supportive criteria+1/2 warning signs\]
  • * MSA group:Adult onset (\>30 years old), sporadic and progressive development, and possessing the following characteristics: 1 Has one of the following two conditions: ① Parkinson's syndrome with levodopa adverse response (bradykinesia, accompanied by muscle rigidity, tremors, or postural instability), ② cerebellar dysfunction: gait ataxia, accompanied by cerebellar articulation disorders, limb ataxia, or cerebellar eye movement disorders; 2. At least one manifestation of autonomic dysfunction is present: ① urinary incontinence (inability to control bladder urination, male with erectile dysfunction), ② orthostatic hypotension (a decrease in systolic blood pressure of ≥ 30mmHg and/or diastolic blood pressure of ≥ 15mmHg after standing for 3 minutes).
  • * PSP group:Clinical diagnosis and likely PSP included in the Chinese progressive supranuclear palsy clinical diagnostic criteria developed by the Parkinson's disease and motor disorders group of the Neurology Branch of the Chinese Medical Association in 2016;
  • * Healthy subjects:Healthy population matched with age and gender in the experimental group In addition to the selected patients, a study will also be conducted on patient data in the reference database of the proposing institution.
  • Exclusion Criteria:
  • * Patients who do not consent to study participation
  • * Secondary Parkinson's syndrome caused by vascular factors, drugs, etc
  • * Severe cognitive impairment, AD, amyotrophic lateral sclerosis and other neurodegenerative diseases

About Yousheng Xiao

Yousheng Xiao is a dedicated clinical trial sponsor committed to advancing medical research and innovation. With a focus on enhancing patient outcomes, the organization collaborates with leading healthcare professionals and institutions to design and conduct rigorous clinical trials. Yousheng Xiao prioritizes ethical standards and regulatory compliance, ensuring the safety and well-being of participants while striving to contribute valuable data to the scientific community. Through a patient-centered approach and a commitment to excellence, Yousheng Xiao aims to facilitate the development of novel therapies and improve healthcare solutions.

Locations

Nanning, Guangxi, China

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0